Other · developed by PepGen
PGN-EDODM1 is an investigational agent given by intravenous infusion. It is studied in myotonic dystrophy type 1.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07220603 | Phase 2 | Myotonic Dystrophy 1 | Recruiting | PEPG |
| NCT06204809 | Phase 1 | Myotonic Dystrophy 1 | Completed | PEPG |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Myotonic Dystrophy 1
Updated Oct 25, 2026. Something wrong or missing? Report it on the PEPG page.
See PEPG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PEPG catalysts and pipeline →